BIAF Stock Summary and Trading Ideas (Bioaffinity Technologies | NASDAQ:BIAF)

bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.

Bioaffinity Technologies trades on the NASDAQ stock market under the symbol BIAF.

As of January 3, 2025, BIAF stock price was flat at $0.94 with 52,031 million shares trading.

BIAF has a beta of 1.39, meaning it tends to be more sensitive to market movements. BIAF has a correlation of 0.03 to the broad based SPY ETF.

BIAF has a market cap of $14.65 million. This is considered a Sub-Micro Cap stock.

Last quarter Bioaffinity Technologies reported $2 million in Revenue and -$.16 earnings per share. This fell short of revenue expectation by $-190,000 and missed earnings estimates by -$.01.

The top ETF exchange traded funds that BIAF belongs to (by Net Assets): VTI, VXF.

BIAF has underperformed the market in the last year with a price return of -38.2% while the SPY ETF gained +27.8%. BIAF has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -49.7% and -5.3%, respectively, while the SPY returned +4.6% and +0.1%, respectively.

BIAF support price is $.85 and resistance is $1.03 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BIAF shares will trade within this expected range on the day.